Tonix Pharmaceuticals (TNXP) is developing TNX-102 SL for treatment of fibromyalgia and Post Traumatic Stress Disorder. We think that Tonix is one of the most undervalued stocks in the market. The four most important trends and catalysts for Tonix are:
1) Fibromyalgia and PTSD are Very Large Problems
FM is a Debilitating Disease - FM takes over patient's lives
Millions of Americans Have FM - Between 5 and 15 million American adults have FM.
FM is a Rapidly Growing Diagnosis - The FDA only recently approved the first drugs for FM.
FM is Linked to PTSD - PTSD affects about 7.7 million American adults every year
2) Large Unmet Need for Sleep Quality in FM...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: